Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For COVID-Impacted Studies, US FDA Loosens Video Conferencing But Tightens Home Infusion Guidance

Executive Summary

Also, use of alternative labs or imaging centers depends upon type of assessment and reason it is being performed, FDA's revised guidance states; missed milestones for postmarketing studies required under accelerated approval will need to be justified.

You may also be interested in...



Cancer Trials Should Focus On Collecting Data ‘Strictly Necessary’ For Assessing Efficacy

In journal article, leaders from academia, industry, NCI and FDA propose building upon pandemic-necessitated flexibilities in clinical research, including making it easier for trial participants to access investigational drugs in their own communities and reduced reporting of uninformative adverse events.

Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going

Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.

Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic

New approaches include delivering study drug from a clinical site directly to a patient’s house through a courier service, as well as use of drones and automated dispensing units; future trials could see a mix of delivery approaches.

Related Content

Topics

UsernamePublicRestriction

Register

PS142180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel